Source-backed comparison of Xeomin and Daxxify botulinum toxin products, covering formulation differences, duration, onset, FDA approvals, and decision factors for informed treatment planning.
Last reviewed: 2026-05-06
15 min read
Ready to explore your options in Istanbul?
Connect with our coordination team for a personalised treatment plan, verified provider matching, and travel logistics support.
Content is educational and planning-oriented. It does not replace diagnosis, treatment, or personalized medical advice from a licensed healthcare professional. Outcomes vary by individual case.
This content is general education and does not replace evaluation by a licensed clinician. If you have symptoms, complications, or urgent concerns, seek in-person medical care.
Key takeaways
Xeomin and Daxxify use fundamentally different stabilization technologies—Xeomin is a purified 'naked' toxin, while Daxxify employs a proprietary peptide system.
Daxxify may offer longer duration (median 6 months) compared to Xeomin (typically 3-4 months), though individual results vary based on metabolism, muscle strength, and injection technique.
Botulinum toxin units are NOT interchangeable between brands—a unit of Xeomin does not equal a unit of Daxxify.
Daxxify's FDA approval is currently limited to glabellar lines only, while Xeomin has broader approved indications for upper facial wrinkles.
Provider experience matters significantly—Daxxify's newer status means less accumulated clinical data among practitioners compared to established products.
Understanding Xeomin and Daxxify
When exploring botulinum toxin treatments for facial wrinkles, you may encounter several brand options. Xeomin and Daxxify represent two distinct approaches to neuromodulation, each with unique formulation characteristics that may influence treatment outcomes. Understanding these differences can help you have informed discussions with your provider about which option may align with your aesthetic goals.
Both products belong to the botulinum toxin type A family and work through the same fundamental mechanism—temporarily blocking nerve signals to specific muscles. However, the way each product is formulated and stabilized sets them apart. These formulation differences may matter for patients with specific preferences, such as those seeking vegan-compatible options or those who have experienced reduced response to other toxins over time.
All botulinum toxin type A products, including Xeomin and Daxxify, function by targeting the SNAP-25 protein, a component required for acetylcholine release at the neuromuscular junction [S1]. When injected into specific facial muscles, the toxin prevents acetylcholine release, temporarily reducing muscle activity that causes dynamic wrinkles.
The effects are not permanent because the nerve eventually forms new SNAP-25 proteins, restoring muscle function over time [S1]. This temporary nature means repeat treatments are necessary to maintain results. The duration of effect varies significantly between individuals based on factors including metabolism, muscle strength, injection technique, and the specific product used [S4].
Understanding this mechanism helps explain why formulation differences matter. The core neurotoxin molecule is similar across products, but the surrounding components—how the toxin is stabilized and delivered—may influence how the body responds to treatment and how long results persist.
Xeomin: The Purified Option
Xeomin, marketed as incobotulinumtoxinA, received FDA approval in 2011 and expanded approval for all upper facial lines in 2024 [S2]. Its distinguishing characteristic is the removal of accessory proteins during manufacturing, resulting in a "naked" 150-kDa neurotoxin that undergoes extensive purification [S2]. This formulation approach distinguishes Xeomin from other botulinum toxins that retain complexing proteins.
The absence of accessory proteins means Xeomin contains only the active neurotoxin component [S2]. This purification process may reduce the potential for antibody formation in some patients, though clinical significance varies among individuals [S2]. For patients who have received multiple treatments over many years and notice reduced response, the purified formulation may be worth discussing with a qualified provider.
Clinical trial data demonstrates comparable efficacy to other botulinum toxin type A products, with duration of effect typically lasting up to 4 months in most patients [S2]. Onset of effect generally occurs within 3-4 days post-injection [S2]. These timelines represent population averages—individual response may vary based on treatment area, dosage, and personal physiology.
Daxxify: The Peptide Innovation
Daxxify (daxibotulinumtoxinA-lanm) represents the newest advancement in neuromodulators, receiving FDA approval in September 2022 [S1]. Its key innovation is the proprietary RTP004 peptide that stabilizes the neurotoxin without using human serum albumin or animal-derived proteins [S1]. This makes Daxxify a vegan-compatible option for patients who prefer to avoid animal-derived ingredients in their treatments.
The peptide-based stabilization system distinguishes Daxxify from protein-based approaches used in other products [S3]. Clinical data from the SAKURA trials showed a median duration of effect at 24 weeks (approximately 6 months), with some patients experiencing results lasting up to 9 months [S5]. This extended duration potential represents a meaningful difference from traditional toxins, though not all patients achieve maximum longevity.
Daxxify also demonstrates notably faster onset of action, with effects visible within 1-2 days compared to the 3-5 days typical of traditional formulations [S3]. This faster onset may appeal to patients planning treatments before specific events who want quicker visible results.
However, Daxxify's FDA approval is currently limited to glabellar lines (frown lines between the eyebrows) [S1]. Use in other treatment areas—such as forehead lines, crow's feet, or other off-label applications—lacks manufacturer dosing guidelines and requires provider judgment [S3].
Key Formulation Differences
Xeomin's purification removes accessory proteins entirely, while Daxxify replaces traditional stabilization with a synthetic peptide system. These differences affect immunogenicity potential, storage requirements, and regulatory approval scopes.
Duration and Onset Comparison
When comparing Xeomin and Daxxify, duration and onset represent two of the most practically relevant factors for treatment planning. Clinical evidence provides population-level data, but individual results may vary substantially based on personal factors.
Duration of Effect
Xeomin typically provides visible improvement for approximately 3-4 months, with clinical trials demonstrating up to 4 months of efficacy in the majority of patients [S2]. This duration aligns closely with other conventional botulinum toxin type A products and represents well-established clinical expectations.
Daxxify's clinical data suggests a median duration of 24 weeks (about 6 months), with the Phase 3 SAKURA trials showing sustained response in many participants through this timeframe [S5]. A subset of patients in these trials experienced effects lasting up to 9 months [S5]. However, individual response varies significantly, and not all patients achieve the longer end of this range.
A 2024 comparative study examining multiple botulinum toxin type A products noted that duration depends heavily on individual metabolism, injection technique, muscle mass in the treatment area, and previous exposure to botulinum toxins [S4]. Patients new to treatment may respond differently than those who have received multiple injections over years.
Onset of Action
Traditional botulinum toxins including Xeomin typically show initial effects within 3-5 days, with full results visible by day 7-14 [S2]. Daxxify's faster onset means visible changes may appear within 1-2 days, with full effects developing more quickly [S3]. This difference may matter for patients wanting faster confirmation of treatment success or those planning treatments close to specific events.
The practical implications of onset timing depend on individual circumstances. For routine maintenance treatments, onset timing may be less significant than duration. For event-driven treatments, the faster onset of Daxxify could offer advantages.
Factors Affecting Individual Response
Individual response to botulinum toxins varies significantly and depends on multiple factors [S4]:
Metabolism and circulation: Patients with faster metabolic rates may process the toxin more quickly
Muscle strength and mass: Stronger muscles may require higher doses or respond differently
Injection technique: Provider experience and precision affect where the toxin distributes
Previous treatments: Patients with long treatment histories may develop varying response patterns
Treatment area: Different facial areas respond differently to the same product
These factors explain why some patients achieve longer or shorter duration than population averages suggest, and why treatment planning should be individualized rather than standardized.
Feature
Xeomin (incobotulinumtoxinA)
Daxxify (daxibotulinumtoxinA)
FDA Approval Year
2011 (expanded 2024)
2022
Approved Treatment Areas
Glabellar lines, forehead lines, crow's feet
Glabellar lines only
Typical Duration
3-4 months
Median 6 months (up to 9 months in some)
Onset of Effect
3-5 days
1-2 days
Stabilization Method
Purified (no accessory proteins)
Peptide-based (RTP004)
Human Serum Albumin
No
No
Animal-Derived Proteins
No
No
FDA Approvals and Regulatory Status
Understanding FDA approval status helps patients understand what indications have been formally evaluated versus what represents off-label use. This distinction matters for informed consent and treatment planning.
Xeomin has the broader regulatory profile of the two products, with FDA approval for all three upper facial line types: glabellar lines (frown lines), forehead lines, and crow's feet [S2]. This means dosing guidelines exist for these treatment areas, and the manufacturer provides specific recommendations for injection technique and dosage. For general information on treatment options, see the injectables-botox treatment information page.
Daxxify's regulatory approval is more limited, currently cleared only for the treatment of glabellar lines [S1]. Use in other facial areas—while potentially performed by experienced providers—falls under off-label application. Off-label use is legal and common in medical practice, but it means manufacturer dosing guidelines and safety data for those specific applications may be limited.
For patients considering Daxxify for areas beyond glabellar lines, discussing the off-label nature of such treatment with your provider is important. Understanding what clinical evidence supports such use, and what experience your provider has with these applications, helps frame realistic expectations.
Provider Experience Considerations
Daxxify's newer market entry means less accumulated clinical experience among practitioners compared to products like Xeomin that have been available for over a decade [S3]. Provider familiarity with a specific product develops through repeated use, observation of patient responses, and refinement of technique over time.
When selecting a provider for either product, asking about their specific experience with the brand being recommended is reasonable. A provider experienced with Xeomin may have different insights than one more familiar with Daxxify. Neither product inherently produces better results—the outcome depends heavily on appropriate patient selection, proper technique, and realistic goal-setting.
For patients traveling to Istanbul for treatment, choosing qualified providers and accredited facilities remains essential regardless of which product you select.
Safety Profile and Risk Considerations
Both Xeomin and Daxxify share the fundamental safety considerations applicable to all botulinum toxin type A products. Understanding these risks helps patients recognize normal versus concerning post-treatment experiences.
Common Adverse Events
Clinical trials for both products report similar patterns of common, mild side effects that typically resolve without intervention [S1][S2]:
Mild brow ptosis (drooping) when toxin migrates beyond intended area
Temporary dry eyes or eyelid swelling
These events occur at similar rates across botulinum toxin products and reflect the mechanical process of injection rather than product-specific reactions [S4].
Serious Risks and Warnings
All botulinum toxins carry a boxed warning about potential spread of effects beyond injection sites [S1]. While rare, this spread can cause serious adverse effects including difficulty breathing, swallowing difficulties, and generalized muscle weakness. These events are more common with higher doses or when treating areas near delicate structures.
Ptosis (drooping) of the brow or eyelid remains the most common clinically significant adverse event when treating upper facial lines. Proper injection technique, appropriate dosing, and provider experience help minimize this risk. Patients experiencing unexpected drooping should contact their provider promptly.
When to Seek Medical Attention
Seek prompt medical evaluation if you experience: difficulty breathing, slurred speech, significant muscle weakness spreading beyond the treatment area, vision changes, or loss of bladder control after any botulinum toxin treatment.
Contraindications and Precautions
Botulinum toxin treatments are not appropriate for everyone. Absolute contraindications include [S1]:
Hypersensitivity to any botulinum toxin product or components
Infection at the planned injection site
History of reaction to previous botulinum toxin treatments
Neuromuscular disorders such as myasthenia gravis or ALS
Pregnancy and breastfeeding
Certain medications that affect neuromuscular function
Bleeding disorders or anticoagulant use
Disclosing your complete medical history to your provider before treatment helps ensure appropriate product selection and safety planning.
Choosing the Right Option for You
Selecting between Xeomin and Daxxify involves weighing several personal factors against the clinical profiles of each product. There is no universally "better" option—the right choice depends on individual circumstances, goals, and priorities.
Questions to Discuss with Your Provider
When evaluating which product may be appropriate, consider discussing these topics with your provider:
Which treatment areas do you want to address? If treating areas beyond glabellar lines, Daxxify would represent off-label use.
How long do you want results to last? If maximizing duration is a priority, Daxxify's longer median duration may be relevant—though at higher per-treatment cost.
How quickly do you want to see results? If faster onset matters, Daxxify's 1-2 day timeline may appeal to you.
Have you responded to previous botulinum toxin treatments? If you've experienced reduced response over time, Xeomin's purified formulation may be worth considering.
Do you have preferences about formulation components? If avoiding animal-derived ingredients is important, both products accommodate this preference.
What is your budget and treatment timeline? Consider both per-treatment costs and how frequently you want to schedule appointments.
Patients Who May Benefit from Xeomin
Xeomin may be particularly suitable for patients who [S2]:
Want treatment for multiple upper facial areas with FDA-approved dosing guidelines
Prefer a product with the longest clinical track record among the two options
Have received multiple treatments over many years and want to try a purified formulation
Value predictable, established dosing protocols across treatment areas
Patients Who May Benefit from Daxxify
Daxxify may be particularly suitable for patients who [S3][S5]:
Prioritize longer duration between treatments if clinical response supports this
Want faster initial onset of visible results
Prefer the peptide-based formulation approach
Are treating glabellar lines specifically and want the product with the longest Phase 3 trial duration data
Accept the off-label status if considering treatment beyond glabellar lines
Units Are Not Interchangeable
Botulinum toxin units are product-specific and cannot be directly converted between brands. A unit of Xeomin does not equal a unit of Daxxify, Botox, or any other brand. Dosing must follow product-specific guidelines, and providers should clearly communicate which product and how many units they are using.
Preparation and Aftercare
Proper preparation and post-treatment care can influence treatment outcomes and minimize potential complications. These guidelines apply broadly to botulinum toxin injections regardless of which product you select.
Before Your Treatment
Preparing appropriately for your appointment supports optimal outcomes:
Avoid blood-thinning medications and supplements (aspirin, ibuprofen, fish oil, vitamin E) for 1-2 weeks before treatment if medically appropriate, to reduce bruising risk
Disclose all medications, supplements, and herbal products you take regularly
Report any previous reactions to botulinum toxin products or other injectable treatments
Avoid alcohol for 24 hours before treatment
Come with a clean face without makeup if possible
Discuss your goals and ensure you understand what the treatment can and cannot accomplish
Before committing to treatment, consider the following verification steps: confirm which product will be used and understand why your provider selected it; review the informed consent document thoroughly; ask about your provider's experience with this specific product; and request to see the product vial if you wish—qualified providers should accommodate reasonable verification requests.
After Your Treatment
Post-treatment care helps maximize results and minimize complications:
Keep your head elevated for 4 hours post-injection and avoid lying down
Do not touch, rub, or massage the injection sites for 24 hours to prevent unintended toxin spread
Avoid strenuous exercise for 24 hours
Avoid alcohol and blood-thinning medications for 24 hours
Avoid saunas, steam rooms, and excessive sun exposure on the day of treatment
Stay upright and avoid bending forward excessively
Normal timelines: initial effects may appear within days, with full results developing over 1-2 weeks. Duration varies, and scheduling follow-up before you leave ensures appropriate timing for touch-up considerations if needed.
Planning for Medical Travel
For patients traveling to Istanbul for injectable treatments, planning ahead supports safe coordination:
Schedule your initial consultation with enough time before any event you want to look your best for
Allow flexibility in your travel dates in case touch-up is needed
Understand what follow-up support is available after you return home
Document your treatment details (product, units, injection sites) for future reference
Keeping records of your treatment—products used, dosing, response timeline, and duration—helps future providers tailor treatments to your individual patterns. Photos taken under consistent conditions can also help track results over time.
Next Steps
Both Xeomin and Daxxify represent legitimate options within the botulinum toxin treatment landscape. Xeomin offers the advantages of broader FDA approval, longer clinical track record, and a purified formulation approach. Daxxify offers the potential advantages of longer duration median, faster onset, and a novel peptide stabilization system.
The optimal choice depends on your specific treatment goals, which areas you want to address, your timeline for results, and your response patterns to previous treatments. Having an informed discussion with a qualified provider who has experience with both products can help clarify which option may better serve your individual needs.
If you're considering injectable treatments during your time in Istanbul, our team can help coordinate with qualified providers and accredited facilities to support your planning.
4.Sirisuthivoranunt S, et al. Dermatology and Therapy. “Comparative Study on the Duration and Efficacy of Various Botulinum Toxin Type A Injections.” 2024. Accessed 2026-02-20.https://pmc.ncbi.nlm.nih.gov/articles/PMC11116321/
5.Carruthers JD, et al. Plastic and Reconstructive Surgery. “SAKURA 1 and SAKURA 2 Investigator Group. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines.” 2020. Accessed 2026-02-20.https://pubmed.ncbi.nlm.nih.gov/31609882/
External links are provided for educational reference. Verify guidance with qualified clinicians and primary sources where appropriate.
